GSK will close the US consumer factory!

[February 20, 2020 / medical information list] Founder group was applied to restructure Peking University pharmaceutical, saying it may affect the equity structure of the company; Quan Yuhua, the independent chairman of Ruikang pharmaceutical, resigned; the listing plan of Bluebird bio gene therapy zynteglo in the United States will be postponed! Essence pharmaceuticals terminates the development of two human monoclonal antibody products Daily fresh medicine news, speed reading club and you pay attention to! As of 24:00 on February 19, according to the reports of 31 provinces (autonomous regions, municipalities directly under the central government) and Xinjiang production and Construction Corps, there are 56303 confirmed cases (including 11864 severe cases), 16155 cured and discharged cases, 2118 dead cases, 74576 confirmed cases (1 case reduced in Jiangxi, Henan and Yunnan), and 4922 suspected cases 589163 close contacts and 126363 close contacts still under medical observation were traced (official website of national health and Health Commission) On September 19, Jiangxi Provincial Drug Administration released the announcement on the suspension of production of Jiangxi Herbal Medicine Co., Ltd It is reported that Cao shopkeeper traditional Chinese Medicine Co., Ltd has submitted an application for suspending the production of herbal pieces to Jiangxi food and Drug Administration for the purpose of transforming the production workshop of herbal pieces into the production workshop of masks (dandelion) On the 20th, Ruikang pharmaceutical announced that it had recently received a written resignation report from Ms Quan Yuhua, an independent director of the company Ms Quan Yuhua applied to resign as an independent director and relevant special committee of the company for personal reasons After resignation, she will no longer hold any post in the company (notice of Ruikang pharmaceutical) Beijing Bank applied to Beijing No 1 middle court to restructure Founder group If the application for restructuring is accepted, Founder Group will enter into the restructuring process, which may have an impact on the company's equity structure, Peking University Pharmaceutical said in a statement Tuesday It is reported that up to now, Founder group holds 85.6% of the equity of the company's shareholder, Peking University Medical (announcement of Peking University Medical) GlaxoSmithKline has announced that it will close its over-the-counter drug manufacturing plant in Carlisle, Pennsylvania, in 2021, affecting about 260 employees (Sina Medical News) The US FDA hopes to get more information about its use in the treatment of zynteglo, a non β 0 / β 0 genotype transfusion dependent β - thalassemia patient aged 12 and over, Bluebird said Tuesday Therefore, the approval application originally scheduled to be completed in the first half of this year is expected to be delayed to the second half of this year (Sina Medical News) A few days ago, enclear therapies announced the completion of round a financing of US $10 million It is reported that the round of financing is used to promote the development of innovative therapies based on medical equipment into the first clinical trial for the treatment of patients with amyotrophic lateral sclerosis (chuangjianhui) Recently, neotx therapeutics, an Israeli biomedical company, announced the completion of the US $45 million round C financing It is reported that the financing will be mainly used for its selective T cell redirection (STR) platform (chuangjianhui) The novel coronavirus rapid detection reagent and new coronavirus rapid detection reagent are being introduced into the emergency examination and approval channel (notice of Wanfu Biology) On the 20th, Lizhu pharmaceutical announced that the company's clinical trial application of "recombinant anti-human IL-17A / F humanized monoclonal antibody injection" jointly declared by Zhuhai Lizhu monoclonal antibody and Beijing xinkanghe biological Co., Ltd., a holding subsidiary of the Japanese company, was approved by the State Food and drug administration The indications of this product are moderate to severe plaque psoriasis (notice of Lizhu pharmaceutical) On the 19 day, the essence pharmaceutical announced that the VEGFR-2 whole human monoclonal antibody and PDL-1 whole human monoclonal antibody products are still in pre clinical research and development stage, and the research results and progress are not in line with the project expectation Considering the actual situation of market competition, it is expected that the benefits of the project will not be obvious and the project will face greater risks After negotiation with kadmon company of the United States, it is decided to terminate the cooperation and authorization agreement (essence pharmaceutical announcement) Sanofi and Roche recently pushed their respective selective estrogen receptor degradation agents sar439859 and rg6171 into key clinical trials, prompting analysts to reexamine this mechanism of action Jefferies, a famous investment bank on Wall Street, expressed a bold view, calling it "a market opportunity of at least $2-3 billion" (Sina Medical News) On the 20th, Incyte announced that its external prescription of JAK inhibitor ruxolitinib reached the main research end point in the second phase 3 clinical trial tree-ad1 for patients with atopic dermatitis It is reported that ruxolitinib cream is an innovative external Janus kinase 1 and 2 inhibitors, which can reduce the systemic side effects of oral JAK inhibitors (yaomingkant) On the 18th, the application for listing of dotiravir / lamivudine, an anti AIDS drug of GlaxoSmithKline, was proposed to be included in the list of priority varieties It is reported that the drug is the first complete, once-a-day single tablet two drug program approved by FDA If it is successfully included in the priority review process, it is expected to be approved and listed in China as soon as possible (yaozhi.com) Recently, immunotep announced that its soluble LAG-3 fusion protein, eftilagimod alpha, was used in combination with keysruda, a blockbuster PD-1 inhibitor of MSD, to obtain positive interim results in phase 2 clinical trials In the first-line treatment of non-small cell lung cancer patients, the combined therapy achieved a total remission rate of 47% (yaomingkant) On the 20th, Seattle genetics and Ansteel announced that the US FDA has granted its antibody coupled drug padcev and pembrolizumab as a breakthrough combination therapy to treat patients with locally advanced or metastatic urothelial carcinoma as a first-line therapy (yaomingkant) Recently, alx oncology company announced that FDA has awarded its leading candidate drug alx148 two fast channel qualification for the first-line treatment of head and neck squamous cell carcinoma patients, and the second-line treatment of HER2 positive gastric or gastroesophageal junction adenocarcinoma patients (Biovalley)